Monitor initial AVLAYAH sales trajectory and payer coverage decisions over the next 2 quarters; key pipeline catalysts include DNL593 data (end 2026) and DNL126 BLA filing (2027). The strong cash position and royalty funding reduce near-term dilution risk.
Price Chart
Executive Summary
Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S. launch of AVLAYAH (tividenofusp alfa) for Hunter syndrome, the first medicine to cross the blood-brain barrier via transferrin receptor. The company also secured $200M in royalty financing and has a robust pipeline with key readouts expected by end of 2026.
Key Financial Metrics
Key Facts
- FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome on March 25, 2026
- First commercial patients dosed in April 2026; launch operational with payers engaged
- Received $200M gross proceeds from Royalty Pharma synthetic royalty funding agreement
- Cash, cash equivalents and marketable securities of $1.05B as of March 31, 2026
- Net loss improved to $128.4M from $133.0M year-over-year
- Pipeline progress: DNL126 (Sanfilippo) Phase 3 prep underway, DNL593 (FTD-GRN) data by end 2026, DNL628 (Alzheimer's) Phase 1b dosed
Financial Impact
AVLAYAH revenue potential uncertain but platform validation and $200M non-dilutive funding strengthen balance sheet; net loss slightly narrowed to $128.4M
Risk Factors
- AVLAYAH commercial adoption and reimbursement uncertainty in Hunter syndrome market
- Confirmatory trial (COMPASS) may affect continued approval
- Pipeline setbacks could outweigh commercial progress
- Takeda's termination of DNL593 collaboration adds development risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290512 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $21.57 $20.06 | ▼ −7.00% | ▼ −6.34% | $20.10 (−6.82%) |
Sep 4, 2026 27d ago | Insider Cluster | $22.08 $20.38 | ▼ −7.70% | ▼ −6.58% | $20.10 (−8.97%) |
Aug 6, 2026 8w ago | 8-K | $24.83 $24.40 | ▼ −1.73% | ▼ −2.13% | $20.10 (−19.05%) |
Jul 27, 2026 9w ago | Press Release | $24.05 $23.15 | ▲ +3.74% | ▲ +6.01% | $20.10 (+16.42%) |
Jun 18, 2026 15w ago | 8-K | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.10 (−13.77%) |
Jun 18, 2026 15w ago | Press Release | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.10 (−13.77%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.02 $23.49 | ▲ +11.75% | ▲ +11.32% | $20.10 (−4.38%) |
May 21, 2026 19w ago | Press Release | $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $20.10 (−7.83%) |
May 7, 2026 21w ago | Press Release | $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $20.10 (+2.45%) |
Apr 3, 2026 25w ago | 8-K | $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $20.10 (+3.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access